Plasma cell infiltrates and renal allograft outcomes in indigenous and non-indigenous people of the Northern Territory of Australia

Nephrology

Volumn 16, Issue 8, 2011, Pages 777-783

  Rogers, Natasha M ^a,b,e   Lawton, Paul D ^c   Jose, Matthew D ^d  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c ROYAL DARWIN HOSPITAL   (Australia)

^d UNIVERSITY OF TASMANIA   (Australia)

^e ROYAL HOBART HOSPITAL   (Australia)

Author keywords

Indigenous; Kidney transplant; Outcome; Plasma cells

Indexed keywords

LEUKOCYTE ANTIGEN;

ABORIGINE; ACUTE GRAFT REJECTION; ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; AUSTRALIA; CELL INFILTRATION; CORRELATION ANALYSIS; ETHNIC GROUP; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSTIMULATION; INCIDENCE; INDIGENOUS PEOPLE; INFECTION; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PLASMA CELL; PRIORITY JOURNAL; SEPTICEMIA;

AUSTRALIA; BIOPSY; COMPLEMENT C4B; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PEPTIDE FRAGMENTS; PLASMA CELLS; POPULATION GROUPS; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84055211967     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2011.01487.x     Document Type: Article

References (22)

1. McDonald S. Indigenous transplant outcomes in Australia: What the ANZDATA Registry tells us. Nephrology 2004;9:S138-43.
2. Rogers N, Lawton P, Jose M. Kidney transplant outcomes in the Indigenous population in the Northern Territory of Australia. Transplantation 2006;82:882-6. (Pubitemid 44564032)
3. Charney D, Nadasdy T, Lo A, Racusen L. Plasma cell-rich acute renal allograft rejection. Transplantation 1999;68:791-7. (Pubitemid 29468197)
4. Desvaux D, Le Gouvello S, Pastural M et al. Acute renal allograft rejection with major interstitial oedema and plasma cell-rich infiltrates: High γ-interferon expression and clinical outcome. Nephrol. Dial. Transplant. 2004;19:933-9. (Pubitemid 38455667)
5. Gärtner V, Eigentler T, Viebahn R. Plasma cell-rich rejection processes in renal transplantation: Morphology and prognostic significance. Transplantation 2006;81:986-91. (Pubitemid 43670430)
6. Lerut E, Kuypers D, Verbeken E et al. Acute rejection in non-compliant renal allograft recipients: A distinct morphology. Clin. Transplant. 2007;21:344-51. (Pubitemid 46711396)
7. Racusen L, Solez K, Colvin R. The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999;55:713-23. (Pubitemid 29082898)
8. Martin L, Charon-Barra C, Bocrie O et al. Detection of plasma cells, C4d deposits and donor-specific antibodies on sequential graft biopsies of renal transplant recipients with chronic dysfunction. Transpl. Immunol. 2010;22:110-14.
9. Xu X, Shi B, Cai M et al. A retrospective study of plasma cell infiltrates in explanted renal allografts. Transplant. Proc. 2008;40:1366-70. (Pubitemid 351853160)
10. Einecke G, Reeve J, Mengel M et al. Expression of B cell and immunoglobulin transcripts is a feature of inflammation in late allografts. Am. J. Transplant. 2008;8:1434-43. (Pubitemid 351989485)
11. Meehan S, Domer P, Josephson M et al. The clinical and pathologic implications of plasmacytic infiltrates in percutaneous renal allograft biopsies. Hum. Pathol. 2001;32:205-15. (Pubitemid 32193719)
12. Fairfax K, Kallies A, Nutt S, Tarlinton D. Plasma cell development: From B-cell subsets to long-term survival niches. Semin. Immunol. 2008;20:49-58.
13. Bernasconi N, Traggiai E, Lanzavecchia A. Maintenance of serologic memory by polyclonal activation of human memory B cells. Science 2002;298:2199-202. (Pubitemid 35471246)
14. Thaunat O, Field A, Dai J et al. Lymphoid neogenesis in chronic rejection: Evidnece for a local humoral alloimmune response. Proc. Natl. Acad. Sci. U. S. A. 2009;102:14723-8. (Pubitemid 41457123)
15. Stegall M, Dean P, Gloor J. Mechanisms of alloantibody production in sensitized renal allograft recipients. Am. J. Transplant. 2009;9:998-1005.
16. Tarazona R, Dela Rosa O, Alonso C et al. Increased expression of NK cell markers on T lymphocytes in aging and chronic activation of the immune system reflects the accumulation of effector/senescent T cells. Mech. Ageing Dev. 2000;121:77-88. (Pubitemid 32115402)
17. Green D, Droin N, Pinkoski M. Activation-induced cell death in T cells. Immunol. Rev. 2003;193:70-81. (Pubitemid 36688041)
18. Rivas M, Weatherly K, Hazzan M et al. Reviving function in CD4+ T cells adapted to persistent systemic antigen. J. Immunol. 2009;183:4284-91.
19. Perry D, Burns J, Pollinger H et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am. J. Transplant. 2009;9:201-9.
20. Everly M, Everly J, Susskind B et al. Bortezomib provides effective therapy for antibody-and cell-mediated acute rejection. Transplantation 2008;86:1754-61.
21. Costes V, Magen V, Legouffe E. The Mil5 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bome marrow biopsy specimens. Hum. Pathol. 1999;30:1405-11. (Pubitemid 30032914)
22. Kemény E, Hirsch H, Eller J, Dürmüller U, Hopfer H, Mihatsch M. Plasma cell infiltrates in polyomavirus nephropathy. Transpl. Int. 2010;23:397-406.